<p>Lyell Immunopharma, Inc.（纳斯达克代码：LYEL - 获取免费报告）在 5 月份的空头头寸显著增加。截至 5 月 15 日，空头头寸总计为 9,710,000 股，比 4 月 30 日的 5,660,000 股增加了 71.6%。该公司的约 8.1% 的股份被做空。根据平均每日交易量 770,900 股，目前的空头头寸比率为 12.6 天。</p>
<p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>另外，HC Wainwright 在 4 月 16 日的报告中重新发布了 “中性” 评级，并将 Lyell Immunopharma 的目标股价设定为 1.00 美元。</p>
<p><strong>查看我们关于 Lyell Immunopharma 的最新报告</strong></p>
<h2>Lyell Immunopharma 上涨 1.9%</h2>
<p>周五，LYEL 上涨 0.01 美元，达到 0.41 美元。该公司的交易量为 865,368 股，而其平均交易量为 1,034,945 股。该公司的 50 日移动平均为 0.44 美元，200 日移动平均为 0.61 美元。该公司的市值为 1.2088 亿美元，市盈率为-0.52，贝塔值为-0.25。Lyell Immunopharma 的年低点为 0.39 美元，年高点为 2.80 美元。</p>
<p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）最后一次公布财报是在 5 月 13 日，报告显示该季度每股收益（EPS）为-0.18 美元，超出分析师共识预期的-0.19 美元 0.01 美元。该季度的收入为 0.01 百万美元。Lyell Immunopharma 的净利润率为-323,792.09%，股本回报率为-34.64%。研究分析师预测 Lyell Immunopharma 在本年度将发布-0.78 的每股收益。</p>
<h2>Lyell Immunopharma 的内部买卖</h2>
<p>在其他新闻中，首席执行官 Lynn Seely 在 3 月 14 日的交易中购买了 175,000 股 Lyell Immunopharma 的股票，平均价格为每股 0.61 美元，总价值为 106,750.00 美元。收购完成后，首席执行官现在持有 712,500 股公司股票，价值 434,625 美元。此次交易使其持股增加了 32.56%。该交易在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。此外，董事 Sumant Ramachandra 在 3 月 21 日的交易中购买了 200,000 股 Lyell Immunopharma 的股票，平均成本为每股 0.58 美元，总价值为 116,000.00 美元。收购后，该董事现在持有 200,000 股公司股票，价值约 116,000 美元。此次交易代表其持股的∞增加。该购买的披露信息可以在这里找到。过去 90 天内，内部人士共购买了 768,640 股公司股票，价值 449,508 美元。内部人士持有公司 25.10% 的股份。</p>
<h2>对 Lyell Immunopharma 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近买卖了该股票的股份。Graham Capital Management L.P.在第四季度购买了 Lyell Immunopharma 的新头寸，价值约 33,000 美元。RPO LLC 在第四季度获得了 Lyell Immunopharma 的新股份，价值约 42,000 美元。Wells Fargo &amp; Company MN 在第四季度将其在 Lyell Immunopharma 的持股增加了 27.8%。Wells Fargo &amp; Company MN 现在持有 94,320 股公司股票，价值 60,000 美元，此前在上个季度又购买了 20,542 股。俄亥俄州公共雇员退休系统在第四季度获得了 Lyell Immunopharma 的新股份，价值约 64,000 美元。最后，SG Americas Securities LLC 在第四季度将其在 Lyell Immunopharma 的持股增加了 102.8%。SG Americas Securities LLC 现在持有 116,748 股公司股票，价值 75,000 美元，此前在上个季度又购买了 59,182 股。机构投资者持有公司 66.05% 的股份。</p>
<h2>Lyell Immunopharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Lyell Immunopharma, Inc 是一家临床阶段的细胞治疗公司，开发针对实体肿瘤患者的 T 细胞重编程技术。该公司利用体外基因重编程技术开发疗法，如 c Jun 过表达和 NR4A3 基因敲除，以赋予 T 细胞抵抗疲劳的能力；以及体外表观遗传重编程技术，包括 Epi R 以生成具有持久干性的人群 T 细胞，以及 Stim R，一种专有合成细胞仿生物。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Lyell Immunopharma</li>
<li>现在值得购买的三只最佳金融科技股票</li>
<li>接近 52 周低点的三只中型股值得关注</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>在动荡时期的三只被忽视的分红股票</li>
<li>如何在 5 个简单步骤中做空股票</li>
<li>AXON：摩托罗拉以 44 亿美元收购，竞争加剧</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
<p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Lyell Immunopharma 并不在名单上。</p>
<p>虽然 Lyell Immunopharma 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LYEL

<p>Lyell Immunopharma, Inc.（纳斯达克代码：LYEL）在 5 月 15 日的空头头寸显著增加，增长了 71.6%，达到 9,710,000 股。这大约占公司股票的 8.1%。目前的空头头寸比率为 12.6 天，基于每日平均交易量为 770,900 股。此外，首席执行官 Lynn Seely 和董事 Sumant Ramachandra 进行了显著的股票购买，增加了他们的持股。机构投资者持有公司 66.05% 的股份，该公司专注于开发针对实体肿瘤的 T 细胞重编程技术</p>

<p>Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 9,710,000 shares, an increase of 71.6% from the April 30th total of 5,660,000 shares. Approximately 8.1% of the shares of the company are sold short. Based on an average daily volume of 770,900 shares, the short-interest ratio is presently 12.6 days.</p>
<div class="lb-trans"><p>Lyell Immunopharma, Inc.（纳斯达克代码：LYEL - 获取免费报告）在 5 月份的空头头寸显著增加。截至 5 月 15 日，空头头寸总计为 9,710,000 股，比 4 月 30 日的 5,660,000 股增加了 71.6%。该公司的约 8.1% 的股份被做空。根据平均每日交易量 770,900 股，目前的空头头寸比率为 12.6 天。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, HC Wainwright reissued a &#34;neutral&#34; rating and set a $1.00 price target on shares of Lyell Immunopharma in a report on Wednesday, April 16th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 4 月 16 日的报告中重新发布了 “中性” 评级，并将 Lyell Immunopharma 的目标股价设定为 1.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Lyell Immunopharma 的最新报告</strong></p>
</div><h2>Lyell Immunopharma Trading Up 1.9%</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 上涨 1.9%</h2>
</div><p>LYEL traded up $0.01 on Friday, reaching $0.41. The company had a trading volume of 865,368 shares, compared to its average volume of 1,034,945. The company has a fifty day moving average of $0.44 and a 200-day moving average of $0.61. The company has a market capitalization of $120.88 million, a P/E ratio of -0.52 and a beta of -0.25. Lyell Immunopharma has a one year low of $0.39 and a one year high of $2.80.</p>
<div class="lb-trans"><p>周五，LYEL 上涨 0.01 美元，达到 0.41 美元。该公司的交易量为 865,368 股，而其平均交易量为 1,034,945 股。该公司的 50 日移动平均为 0.44 美元，200 日移动平均为 0.61 美元。该公司的市值为 1.2088 亿美元，市盈率为-0.52，贝塔值为-0.25。Lyell Immunopharma 的年低点为 0.39 美元，年高点为 2.80 美元。</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The firm had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Research analysts predict that Lyell Immunopharma will post -0.78 EPS for the current year.</p>
<div class="lb-trans"><p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）最后一次公布财报是在 5 月 13 日，报告显示该季度每股收益（EPS）为-0.18 美元，超出分析师共识预期的-0.19 美元 0.01 美元。该季度的收入为 0.01 百万美元。Lyell Immunopharma 的净利润率为-323,792.09%，股本回报率为-34.64%。研究分析师预测 Lyell Immunopharma 在本年度将发布-0.78 的每股收益。</p>
</div><h2>Insider Buying and Selling at Lyell Immunopharma</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 的内部买卖</h2>
</div><p>In other news, CEO Lynn Seely purchased 175,000 shares of Lyell Immunopharma stock in a transaction dated Friday, March 14th. The stock was bought at an average price of $0.61 per share, with a total value of $106,750.00. Following the completion of the acquisition, the chief executive officer now owns 712,500 shares in the company, valued at $434,625. The trade was a 32.56% increase in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director Sumant Ramachandra purchased 200,000 shares of Lyell Immunopharma stock in a transaction dated Friday, March 21st. The shares were purchased at an average cost of $0.58 per share, with a total value of $116,000.00. Following the acquisition, the director now owns 200,000 shares of the company's stock, valued at approximately $116,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 768,640 shares of company stock worth $449,508 over the last 90 days. Insiders own 25.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Lynn Seely 在 3 月 14 日的交易中购买了 175,000 股 Lyell Immunopharma 的股票，平均价格为每股 0.61 美元，总价值为 106,750.00 美元。收购完成后，首席执行官现在持有 712,500 股公司股票，价值 434,625 美元。此次交易使其持股增加了 32.56%。该交易在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。此外，董事 Sumant Ramachandra 在 3 月 21 日的交易中购买了 200,000 股 Lyell Immunopharma 的股票，平均成本为每股 0.58 美元，总价值为 116,000.00 美元。收购后，该董事现在持有 200,000 股公司股票，价值约 116,000 美元。此次交易代表其持股的∞增加。该购买的披露信息可以在这里找到。过去 90 天内，内部人士共购买了 768,640 股公司股票，价值 449,508 美元。内部人士持有公司 25.10% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Lyell Immunopharma</h2>
<div class="lb-trans"><h2>对 Lyell Immunopharma 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. Graham Capital Management L.P. bought a new position in Lyell Immunopharma in the 4th quarter valued at about $33,000. RPO LLC acquired a new stake in Lyell Immunopharma in the 4th quarter valued at about $42,000. Wells Fargo &amp; Company MN lifted its holdings in Lyell Immunopharma by 27.8% in the 4th quarter. Wells Fargo &amp; Company MN now owns 94,320 shares of the company's stock valued at $60,000 after acquiring an additional 20,542 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Lyell Immunopharma in the 4th quarter valued at about $64,000. Finally, SG Americas Securities LLC lifted its holdings in Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock valued at $75,000 after acquiring an additional 59,182 shares during the last quarter. Institutional investors own 66.05% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该股票的股份。Graham Capital Management L.P.在第四季度购买了 Lyell Immunopharma 的新头寸，价值约 33,000 美元。RPO LLC 在第四季度获得了 Lyell Immunopharma 的新股份，价值约 42,000 美元。Wells Fargo &amp; Company MN 在第四季度将其在 Lyell Immunopharma 的持股增加了 27.8%。Wells Fargo &amp; Company MN 现在持有 94,320 股公司股票，价值 60,000 美元，此前在上个季度又购买了 20,542 股。俄亥俄州公共雇员退休系统在第四季度获得了 Lyell Immunopharma 的新股份，价值约 64,000 美元。最后，SG Americas Securities LLC 在第四季度将其在 Lyell Immunopharma 的持股增加了 102.8%。SG Americas Securities LLC 现在持有 116,748 股公司股票，价值 75,000 美元，此前在上个季度又购买了 59,182 股。机构投资者持有公司 66.05% 的股份。</p>
</div><h2>Lyell Immunopharma Company Profile</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.</p>
<div class="lb-trans"><p>Lyell Immunopharma, Inc 是一家临床阶段的细胞治疗公司，开发针对实体肿瘤患者的 T 细胞重编程技术。该公司利用体外基因重编程技术开发疗法，如 c Jun 过表达和 NR4A3 基因敲除，以赋予 T 细胞抵抗疲劳的能力；以及体外表观遗传重编程技术，包括 Epi R 以生成具有持久干性的人群 T 细胞，以及 Stim R，一种专有合成细胞仿生物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>3 Overlooked Dividend Plays for Income in Volatile Times</li>
<li>How to Short a Stock in 5 Easy Steps</li>
<li>AXON: Competition Intensifies as Motorola Makes $4.4B Acquisition</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Lyell Immunopharma</li>
<li>现在值得购买的三只最佳金融科技股票</li>
<li>接近 52 周低点的三只中型股值得关注</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>在动荡时期的三只被忽视的分红股票</li>
<li>如何在 5 个简单步骤中做空股票</li>
<li>AXON：摩托罗拉以 44 亿美元收购，竞争加剧</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Lyell Immunopharma 并不在名单上。</p>
</div><p>While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lyell Immunopharma 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lyell Immunopharma, Inc.（纳斯达克股票代码：LYEL）的空头头寸扩大了 71.6%